Health, Biotech & Nutrition R&D Companies UK

Johnson & Johnson Services Inc is a global healthcare giant specialising in the development of advanced medical technologies, pharmaceuticals, and consumer health products. Their work focuses on integrating genomic data into clinical practice to improve patient outcomes and accelerate the diagnosis of complex conditions. Through large-scale research initiatives, they aim to bridge the gap between fundamental genomic science and practical, scalable healthcare solutions.

The University of Surrey is a leading UK research institution that bridges the gap between fundamental academic inquiry and industrial application. Their work spans diverse domains including advanced telecommunications, sustainable food systems, AI-driven data marketplaces, and aerospace manufacturing. By leveraging a broad network of industry partners, they translate complex scientific research into practical solutions for societal and economic challenges.

The University of Aberdeen is a research-intensive academic institution that leverages its expertise in biotechnology, data science, and engineering to solve complex industrial and societal challenges. Through a robust portfolio of Knowledge Transfer Partnerships and collaborative R&D, the university translates fundamental research into practical applications across sectors including healthcare, energy, and agriculture. Their work has evolved from traditional academic inquiry to a highly commercialised model of technology transfer, focusing on sustainability, digital transformation, and health innovation.

Scotland's Rural College (SRUC) is a leading academic and research institution specialising in agricultural science, veterinary medicine, and environmental sustainability. They bridge the gap between fundamental research and practical on-farm application, focusing on livestock health, soil biodiversity, and the transition of the UK agricultural sector toward Net Zero. Their work has evolved from traditional agricultural research to a highly collaborative, technology-driven approach that integrates AI, robotics, and circular economy principles into food production systems.

Genomics England is a government-owned company established to deliver the 100,000 Genomes Project and advance the clinical application of genomic medicine within the NHS. They develop large-scale data infrastructure and analytical frameworks to integrate whole genome sequencing into routine clinical care and cancer research. Their work focuses on bridging the gap between complex genomic data and actionable clinical insights for patient benefit.

Mologic is a diagnostics company specialising in point-of-care tests for infectious diseases, respiratory conditions, and animal health. They develop lateral flow assays, virus-like particle vaccines, and integrated digital diagnostic platforms, with a strong emphasis on affordable testing for global health and low-resource settings. Their work has evolved from stratified medicine projects for COPD and sepsis to large-scale global health initiatives in sub-Saharan Africa and, more recently, livestock diagnostics.

Autolus is a clinical-stage biopharmaceutical company specialising in the development of next-generation programmed T-cell therapies for the treatment of cancer. Their work focuses on engineering CAR T-cell products that target both liquid and solid tumours, while simultaneously addressing the complex manufacturing and supply chain challenges inherent in personalised medicine. Over their grant history, they have evolved from fundamental research into CAR T-cell mechanisms to leading large-scale industrial consortia focused on the digitalisation and standardisation of advanced therapy manufacturing processes.

Cellular Therapeutics is a biotechnology company specialising in the development of tumour-infiltrating lymphocyte (TIL) therapies for solid tumours, with a focus on manufacturing processes and clinical translation. Their work has evolved from early microfluidic cell processing tools to leading clinical trials of engineered TILs for ovarian cancer, supported by a strong network of academic, NHS, and industry partners.

Bactobio discovers novel antibiotics and fungicides from previously unculturable microbes using synthetic biology, next-generation sequencing, and machine learning. The company addresses antimicrobial resistance and crop diseases by accessing the 99% of microbes that cannot be cultured in the lab, screening for new bioactive compounds. Their work has evolved from targeted antibiotic discovery to broad high-throughput screening with AI integration.

Oxford Biomedica is a global leader in the development and manufacture of lentiviral vectors, providing essential platform technologies for cell and gene therapies. Their work spans the entire value chain from clinical development to commercial-scale GMP manufacturing, with a focus on integrating advanced robotics, digital frameworks, and process analytical technologies. The company has evolved from a pioneer in in vivo delivery to a large-scale manufacturer supporting major commercial products like Kymriah.

Arecor is a biotherapeutic formulation company specialising in developing stable formulations of therapeutic proteins, particularly for diabetes care. Their proprietary formulation technology enables improved stability and action profiles for insulin and glucagon, addressing unmet needs in glucose management. Their work has evolved from early proof-of-concept projects to clinical-stage products, including ultra-long acting, superfast acting, and ultra-rapid insulins, with a focus on enabling closed-loop artificial pancreas systems.

E.ON Energy Solutions is a major energy provider that leverages its scale to lead large-scale R&D initiatives focused on grid decarbonisation and social infrastructure. Their work spans the integration of vehicle-to-grid technologies and smart local energy systems to the development of housing solutions that support healthy ageing and independent living. By bridging the gap between energy utility management and social care, they aim to address both the technical challenges of the energy transition and the societal pressures of an ageing population.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that has developed a proprietary platform technology based on bicyclic peptides, known as Bicycles. Their work focuses on creating a new class of therapeutics that combine the high affinity and specificity of antibodies with the small size and chemical versatility of small molecules. Across their grant history, they have evolved from feasibility studies in antibiotic discovery to applying their modular platform to address infectious diseases, including COVID-19 and multi-drug resistant bacterial infections.

Cobra Biologics Limited is a contract development and manufacturing organisation (CDMO) specialising in the production of viral vectors and plasmid DNA for gene therapy applications. The company focuses on developing scalable, cost-effective bioprocessing platforms to accelerate the transition of advanced therapies from clinical trials to commercial supply. Their work has evolved from early-stage process development to large-scale infrastructure investment, establishing the UK as a key hub for gene therapy manufacturing.

Dogtooth Technologies is an agricultural robotics company that develops autonomous soft fruit harvesting systems, primarily for strawberries and raspberries. Their technology combines computer vision, machine learning, and robotic manipulation to address labour shortages and reduce food waste in horticulture. Over a decade of Innovate UK-funded R&D, they have evolved from proof-of-concept prototypes to commercial-scale robots deployed in UK and overseas farms.